{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:21:54Z","timestamp":1793899314122,"version":"4.8.0"},"reference-count":86,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T00:00:00Z","timestamp":1670198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Molecular therapeutic targets in growth hormone (GH)-secreting adenomas range from well-characterized surface receptors that recognize approved drugs, to surface and intracellular markers that are potential candidates for new drug development. Currently available medical therapies for patients with acromegaly bind to somatostatin receptors, GH receptor, or dopamine receptors, and lead to attainment of disease control in most patients. The degree of control is variable: however, correlates with both disease aggressiveness and tumor factors that predict treatment response including somatostatin receptor subtype expression, granulation pattern, kinases and their receptors, and other markers of proliferation. A better understanding of the mechanisms underlying these molecular markers and their relationship to outcomes holds promise for expanding treatment options as well as a more personalized approach to treating patients with acromegaly.<\/jats:p>","DOI":"10.3389\/fendo.2022.1068061","type":"journal-article","created":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T00:07:57Z","timestamp":1670198877000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Molecular targets in acromegaly"],"prefix":"10.3389","volume":"13","author":[{"given":"Artak","family":"Labadzhyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shlomo","family":"Melmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41572-019-0071-6","article-title":"Acromegaly","volume":"5","author":"Colao","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1810772","article-title":"Pituitary-tumor endocrinopathies","volume":"382","author":"Melmed","year":"2020","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnac010","article-title":"Clinical biology of the pituitary adenoma","author":"Melmed","year":"2022","journal-title":"Endocr Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1172\/JCI39375","article-title":"Acromegaly pathogenesis and treatment","volume":"119","author":"Melmed","year":"2009","journal-title":"J Clin Invest"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsb1503104","article-title":"Precision medicine\u2013personalized, problematic, and promising","volume":"372","author":"Jameson","year":"2015","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-3653","article-title":"Pituitary medicine from discovery to patient-focused outcomes","volume":"101","author":"Melmed","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1126\/science.1126100","article-title":"Pituitary adenoma predisposition caused by germline mutations in the AIP gene","volume":"312","author":"Vierimaa","year":"2006","journal-title":"Science"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-1274","article-title":"Somatic GNAS mutation causes widespread and diffuse pituitary disease in acromegalic patients with McCune-albright syndrome","volume":"97","author":"Vortmeyer","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1210\/jcem.78.2.8106629","article-title":"Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors","volume":"78","author":"Greenman","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.79.3.7521350","article-title":"Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage","volume":"79","author":"Greenman","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.1.251","article-title":"Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney","volume":"89","author":"Yamada","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119225","article-title":"Somatostatin receptor subtype specificity in human fetal pituitary cultures. differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation","volume":"99","author":"Shimon","year":"1997","journal-title":"J Clin Invest"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-018-0058-5","article-title":"A consensus statement on acromegaly therapeutic outcomes","volume":"14","author":"Melmed","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-3757","article-title":"Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis","volume":"99","author":"Carmichael","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1993.2122","article-title":"Cloning, functional expression and pharmacological characterization of a fourth (hSSTR4) and a fifth (hSSTR5) human somatostatin receptor subtype","volume":"195","author":"Yamada","year":"1993","journal-title":"Biochem Biophys Res Commun"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1210\/endo.133.6.8243278","article-title":"Tissue distribution of somatostatin receptor subtype messenger ribonucleic acid in the rat","volume":"133","author":"Bruno","year":"1993","journal-title":"Endocrinology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/00129039-200006000-00007","article-title":"Expression of the five different somatostatin receptor subtypes in endocrine cells of the pancreas","volume":"8","author":"Portela-Gomes","year":"2000","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-1919","article-title":"Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro","volume":"94","author":"Lesche","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(14)70169-X","article-title":"Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial","volume":"2","author":"Gadelha","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.143228","article-title":"Antagonizing somatostatin receptor subtype 2 and 5 reduces blood glucose in a gut- and GLP-1R-dependent manner","volume":"6","author":"Jepsen","year":"2021","journal-title":"JCI Insight"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2468","article-title":"A structural and functional acromegaly classification","volume":"100","author":"Cuevas-Ramos","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-012-0445-1","article-title":"Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience","volume":"16","author":"Brzana","year":"2013","journal-title":"Pituitary"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-1986","article-title":"Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas","volume":"93","author":"Pl\u00f6ckinger","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-00135","article-title":"In vitro head-to-Head comparison between octreotide and pasireotide in GH-secreting pituitary adenomas","volume":"102","author":"Gatto","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-1826","article-title":"Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly","volume":"94","author":"Neto","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-15-0832","article-title":"Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study","volume":"174","author":"Iacovazzo","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.13107","article-title":"Epigenetic and post-transcriptional regulation of somatostatin receptor subtype 5 (SST","volume":"16","author":"Pedraza-Arevalo","year":"2022","journal-title":"Mol Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/330537a0","article-title":"Growth hormone receptor and serum binding protein: purification, cloning and expression","volume":"330","author":"Leung","year":"1987","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.88.10.4498","article-title":"A systematic mutational analysis of hormone-binding determinants in the human growth hormone receptor","volume":"88","author":"Bass","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1126\/science.1948064","article-title":"Dimerization of the extracellular domain of the human growth hormone receptor by a single hormone molecule","volume":"254","author":"Cunningham","year":"1991","journal-title":"Science"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06844-1","article-title":"Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist","volume":"358","author":"van der Lely","year":"2001","journal-title":"Lancet"},{"key":"B32","doi-asserted-by":"publisher","first-page":":e3236\u2013e3245","DOI":"10.1210\/clinem\/dgaa444","article-title":"Cost-effectiveness and efficacy of a novel combination regimen in acromegaly: A prospective, randomized trial","volume":"105","author":"Bonert","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B33","doi-asserted-by":"publisher","first-page":"A526","DOI":"10.1210\/jendso\/bvac150.1095","article-title":"OR27-4 placebo-controlled and open-label extension study of a novel hepatic-targeted antisense cimdelirsen (IONIS-GHR-LRx) under investigation in acromegaly patients","volume":"6","author":"Bhanot","year":"2022","journal-title":"J Endocr Soc"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-17-0549","article-title":"MECHANISMS IN ENDOCRINOLOGY: Clinical and pharmacogenetic aspects of the growth hormone receptor polymorphism","volume":"177","author":"Boguszewski","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.80.11.7593452","article-title":"Cellular localization of the growth hormone receptor\/binding protein in the human anterior pituitary gland","volume":"80","author":"Mertani","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2003.01851.x","article-title":"Reduced expression of the growth hormone and type 1 insulin-like growth factor receptors in human somatotroph tumours and an analysis of possible mutations of the growth hormone receptor","volume":"59","author":"Kola","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-16-0140","article-title":"In vitro impact of pegvisomant on growth hormone-secreting pituitary adenoma cells","volume":"23","author":"Cuny","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1152\/physrev.1998.78.1.189","article-title":"Dopamine receptors: from structure to function","volume":"78","author":"Missale","year":"1998","journal-title":"Physiol Rev"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.88.5.1859","article-title":"D1 and D2 dopamine receptor mRNA in rat brain","volume":"88","author":"Weiner","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-016-0778-2","article-title":"Somatostatin and dopamine receptor regulation of pituitary somatotroph adenomas","volume":"20","author":"Ben-Shlomo","year":"2017","journal-title":"Pituitary"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-72-3-675","article-title":"Effects of dexamethasone on growth hormone (GH)-releasing hormone, arginine- and dopaminergic stimulated GH secretion, and total plasma insulin-like growth factor-I concentrations in normal male volunteers","volume":"72","author":"Miell","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-2443","article-title":"Place of cabergoline in acromegaly: a meta-analysis","volume":"96","author":"Sandret","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1101\/gad.1486806","article-title":"Cadherins in development: cell adhesion, sorting, and tissue morphogenesis","volume":"20","author":"Halbleib","year":"2006","journal-title":"Genes Dev"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-2197","article-title":"The expression of e-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response","volume":"95","author":"Fougner","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1310589110","article-title":"Growth hormone is a cellular senescence target in pituitary and nonpituitary cells","volume":"110","author":"Chesnokova","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B46","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/j.1365-2265.2011.04163.x","article-title":"Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly","volume":"76","author":"Fougner","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.16173","article-title":"Predictive and prognostic significance of tumour subtype, SSTR1-5 and e-cadherin expression in a well-defined cohort of patients with acromegaly","volume":"25","author":"Soukup","year":"2021","journal-title":"J Cell Mol Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.13851","article-title":"E-cadherin expression is associated with somatostatin analogue response in acromegaly","volume":"23","author":"Venegas-Moreno","year":"2019","journal-title":"J Cell Mol Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-11-0066","article-title":"Expression and function of ErbB receptors and ligands in the pituitary","volume":"18","author":"Cooper","year":"2011","journal-title":"Endocr Relat Cancer"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000344","article-title":"Role of tyrosine kinase inhibitors in the treatment of pituitary tumours: from bench to bedside","volume":"24","author":"Ben-Shlomo","year":"2017","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa805","article-title":"EGFR\/ErbB2-targeting lapatinib therapy for aggressive prolactinomas","volume":"106","author":"Cooper","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1124\/pr.109.002436","article-title":"Beyond desensitization: physiological relevance of arrestin-dependent signaling","volume":"62","author":"Luttrell","year":"2010","journal-title":"Pharmacol Rev"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1210\/en.2013-1672","article-title":"\u03b2-arrestin 1 and 2 and G protein-coupled receptor kinase 2 expression in pituitary adenomas: role in the regulation of response to somatostatin analogue treatment in patients with acromegaly","volume":"154","author":"Gatto","year":"2013","journal-title":"Endocrinology"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-15-0391","article-title":"Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly","volume":"174","author":"Gatto","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.13427","article-title":"Molecular evidence and clinical importance of \u03b2-arrestins expression in patients with acromegaly","volume":"22","author":"Coelho","year":"2018","journal-title":"J Cell Mol Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1210\/edrv-4-3-271","article-title":"Pathophysiology of acromegaly","volume":"4","author":"Melmed","year":"1983","journal-title":"Endocr Rev"},{"key":"B57","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1530\/EJE-13-0134","article-title":"Molecular and functional properties of densely and sparsely granulated GH-producing pituitary adenomas","volume":"169","author":"Mayr","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-10-0586","article-title":"Relationship between cytokeratin staining patterns and clinico-pathological features in somatotropinomae","volume":"163","author":"Bakhtiar","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-12-0864","article-title":"Granulation pattern, but not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-naive patients with somatotroph adenomas","volume":"168","author":"Larkin","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-2513","article-title":"Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families","volume":"92","author":"Daly","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1530\/EC-19-0027","article-title":"AIP and MEN1 mutations and AIP immunohistochemistry in pituitary adenomas in a tertiary referral center","volume":"8","author":"Daly","year":"2019","journal-title":"Endocr Connect"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-12-0322","article-title":"Somatostatin analogues increase AIP expression in somatotropinomas, irrespective of gsp mutations","volume":"20","author":"Jaffrain-Rea","year":"2013","journal-title":"Endocr Relat Cancer"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-15-0205","article-title":"cAMP-specific PDE4 phosphodiesterases and AIP in the pathogenesis of pituitary tumors","volume":"23","author":"Bolger","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2014.50","article-title":"AIP inactivation leads to pituitary tumorigenesis through defective g\u03b1i-cAMP signaling","volume":"34","author":"Tuominen","year":"2015","journal-title":"Oncogene"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14706","article-title":"Molecular genetic testing in the management of pituitary disease","volume":"97","author":"Coopmans","year":"2022","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-015-0662-5","article-title":"Impact of gsp mutations in somatotroph pituitary adenomas on growth hormone response to somatostatin analogs: a meta-analysis","volume":"18","author":"Efstathiadou","year":"2015","journal-title":"Pituitary"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-18-0565","article-title":"Molecular profiling for acromegaly treatment: a validation study","volume":"27","author":"Puig-Domingo","year":"2020","journal-title":"Endocr Relat Cancer"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2661","article-title":"Pegvisomant for the treatment of gsp-mediated growth hormone excess in patients with McCune-albright syndrome","volume":"91","author":"Akintoye","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1126\/science.285.5426.418","article-title":"Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis","volume":"285","author":"Zou","year":"1999","journal-title":"Science"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/ng997","article-title":"Human securin interacts with p53 and modulates p53-mediated transcriptional activity and apoptosis","volume":"32","author":"Bernal","year":"2002","journal-title":"Nat Genet"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0804810105","article-title":"p21(Cip1) restrains pituitary tumor growth","volume":"105","author":"Chesnokova","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2006.02630.x","article-title":"Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study","volume":"65","author":"Filippella","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/16.10.2814","article-title":"Regulation of apoptosis and cell cycle arrest by Zac1, a novel zinc finger protein expressed in the pituitary gland and the brain","volume":"16","author":"Spengler","year":"1997","journal-title":"EMBO J"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-1189","article-title":"Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression","volume":"66","author":"Theodoropoulou","year":"2006","journal-title":"Cancer Res"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-1111","article-title":"Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway","volume":"97","author":"Chahal","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B76","volume-title":"WHO classification of tumours of endocrine organs","author":"Lloyd","year":"2017"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-0126","article-title":"Prognostic significance of the ki-67 labeling index in growth hormone-secreting pituitary adenomas","volume":"93","author":"Fusco","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.11.7986","article-title":"Effects of octreotide treatment on the proliferation and apoptotic index of GH-secreting pituitary adenomas","volume":"86","author":"Losa","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-021-02009-8","article-title":"RET signalling provides tumorigenic mechanism and tissue specificity for AIP-related somatotrophinomas","volume":"40","author":"Garcia-Rendueles","year":"2021","journal-title":"Oncogene"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1093\/neuros\/nyx020","article-title":"Long-term endocrine outcomes following endoscopic endonasal transsphenoidal surgery for acromegaly and associated prognostic factors","volume":"81","author":"Babu","year":"2017","journal-title":"Neurosurgery"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030461","article-title":"Transsphenoidal surgery for pituitary tumors in the united states, 1996-2000: mortality, morbidity, and the effects of hospital and surgeon volume","volume":"88","author":"Barker","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1002\/path.833","article-title":"CDKN2A\/p16 inactivation is related to pituitary adenoma type and size","volume":"193","author":"Seemann","year":"2001","journal-title":"J Pathol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.84.10.6066","article-title":"Low expression of the cell cycle inhibitor p27Kip1 in normal corticotroph cells, corticotroph tumors, and malignant pituitary tumors","volume":"84","author":"Lidhar","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1007\/s00701-014-2230-6","article-title":"An analysis of granulation patterns, MIB-1 proliferation indices and p53 expression in 101 patients with acromegaly","volume":"156","author":"Sarkar","year":"2014","journal-title":"Acta Neurochir (Wien)"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2007.10.004","article-title":"Role of ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas","volume":"39","author":"Gejman","year":"2008","journal-title":"Hum Pathol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1007\/s10143-016-0740-9","article-title":"Atypical pituitary adenomas: clinical characteristics and role of ki-67 and p53 in prognostic and therapeutic evaluation. a series of 50 patients","volume":"40","author":"Del Basso De Caro","year":"2017","journal-title":"Neurosurg Rev"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1068061\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T00:08:01Z","timestamp":1670198881000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1068061\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,5]]},"references-count":86,"alternative-id":["10.3389\/fendo.2022.1068061"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.1068061","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,5]]},"article-number":"1068061"}}